Announces three-year business strategy and commercial growth drivers, targeting up to 10% revenue growth in 2026 Expects to expand seasonal vaccine franchise from three to up to six approved products ...

Non-dilutive financing from premier lender bolsters strong balance sheet and provides increased flexibility Company reiterates 2025 financial guidance provided on 3Q25 earnings call and targets cash ...

In addition to Evercore ISI, Moderna also received a Hold from Needham’s Joseph Stringer in a report issued today. However, on the same day, Leerink Partners maintained a Sell rating on Moderna ...

In addition to RBC Capital, Moderna also received a Hold from Needham’s Joseph Stringer in a report issued today. However, on the same day, UBS maintained a Buy rating on Moderna (NASDAQ: MRNA).

In a Phase 3 trial of more than 18,000 volunteers across three countries, an mRNA influenza vaccine from Pfizer has ...

The Washington State Department of Health has announced that H5N5, a bird flu strain that has never been detected in humans ...

Moderna’s stock has seen a notable shift in sentiment after its fair value estimate was cut from $40.30 to $37.32. This change reflects revised expectations for the company's long-term potential. The ...

Washington reports world's first fatal human H5N5 bird flu case; officials say risk to public remains low, monitoring ...

Schwab US Dividend Equity ETF ( $SCHD ) has risen by 0.37% in the past week. It has experienced a 5-day net outflow of $54.69 million. This is ...